市中肺炎（CAP）の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Community Acquired Pneumonia (CAP) Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00225 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、市中肺炎（CAP）の世界市場を広く調査・分析し、今後の市場展望をまとめております。市中肺炎（CAP）の種類別市場規模（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養）、用途別市場規模（病院・診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Merck、Biotest、Astrazeneca、Melinta Therapeutics、Bioaegis Therapeutics、Paratek Pharmaceuticals、Kyorin Pharmaceutical、C10 Pharma、Nabriva Therapeutics ・地域別グローバル市場分析 2015年-2020年 ・市中肺炎（CAP）の北米市場（アメリカ、カナダ、メキシコ） ・市中肺炎（CAP）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・市中肺炎（CAP）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・市中肺炎（CAP）の南米市場（ブラジル、アルゼンチン） ・市中肺炎（CAP）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：胸部X線/X線撮影、喀痰グラム染色/培養、血液培養 ・用途別分析：病院・診療所、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Community Acquired Pneumonia (CAP) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Community Acquired Pneumonia (CAP) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Community Acquired Pneumonia (CAP) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Community Acquired Pneumonia (CAP) market has been segmented into:
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures

By Application, Community Acquired Pneumonia (CAP) has been segmented into:
Hospitals and Clinics
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Community Acquired Pneumonia (CAP) market presented in the report. This section sheds light on the sales growth of different regional and country-level Community Acquired Pneumonia (CAP) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Community Acquired Pneumonia (CAP) market.

The report offers in-depth assessment of the growth and other aspects of the Community Acquired Pneumonia (CAP) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Community Acquired Pneumonia (CAP) Market Share Analysis
Community Acquired Pneumonia (CAP) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Community Acquired Pneumonia (CAP) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Community Acquired Pneumonia (CAP) sales, revenue and market share for each player covered in this report.

The major players covered in Community Acquired Pneumonia (CAP) are:
Pfizer
Merck
Biotest
Astrazeneca
Melinta Therapeutics
Bioaegis Therapeutics
Paratek Pharmaceuticals
Kyorin Pharmaceutical
C10 Pharma
Nabriva Therapeutics

レポート目次

---

Table of Contents

1 Community Acquired Pneumonia (CAP) Market Overview
1.1 Product Overview and Scope of Community Acquired Pneumonia (CAP)
1.2 Classification of Community Acquired Pneumonia (CAP) by Type
1.2.1 Global Community Acquired Pneumonia (CAP) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type in 2019
1.2.3 Chest X-ray/Radiography
1.2.4 Sputum Gram Stain and/or Culture
1.2.5 Blood Cultures
1.3 Global Community Acquired Pneumonia (CAP) Market by Application
1.3.1 Overview: Global Community Acquired Pneumonia (CAP) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Global Community Acquired Pneumonia (CAP) Market by Regions
1.4.1 Global Community Acquired Pneumonia (CAP) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Community Acquired Pneumonia (CAP) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Community Acquired Pneumonia (CAP) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Community Acquired Pneumonia (CAP) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Community Acquired Pneumonia (CAP) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Community Acquired Pneumonia (CAP) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Community Acquired Pneumonia (CAP) Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Merck SWOT Analysis
2.2.4 Merck Product and Services
2.2.5 Merck Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Biotest
2.3.1 Biotest Details
2.3.2 Biotest Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Biotest SWOT Analysis
2.3.4 Biotest Product and Services
2.3.5 Biotest Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Astrazeneca
2.4.1 Astrazeneca Details
2.4.2 Astrazeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Astrazeneca SWOT Analysis
2.4.4 Astrazeneca Product and Services
2.4.5 Astrazeneca Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.5 Melinta Therapeutics
2.5.1 Melinta Therapeutics Details
2.5.2 Melinta Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Melinta Therapeutics SWOT Analysis
2.5.4 Melinta Therapeutics Product and Services
2.5.5 Melinta Therapeutics Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bioaegis Therapeutics
2.6.1 Bioaegis Therapeutics Details
2.6.2 Bioaegis Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bioaegis Therapeutics SWOT Analysis
2.6.4 Bioaegis Therapeutics Product and Services
2.6.5 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.7 Paratek Pharmaceuticals
2.7.1 Paratek Pharmaceuticals Details
2.7.2 Paratek Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Paratek Pharmaceuticals SWOT Analysis
2.7.4 Paratek Pharmaceuticals Product and Services
2.7.5 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.8 Kyorin Pharmaceutical
2.8.1 Kyorin Pharmaceutical Details
2.8.2 Kyorin Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Kyorin Pharmaceutical SWOT Analysis
2.8.4 Kyorin Pharmaceutical Product and Services
2.8.5 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.9 C10 Pharma
2.9.1 C10 Pharma Details
2.9.2 C10 Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 C10 Pharma SWOT Analysis
2.9.4 C10 Pharma Product and Services
2.9.5 C10 Pharma Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
2.10 Nabriva Therapeutics
2.10.1 Nabriva Therapeutics Details
2.10.2 Nabriva Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Nabriva Therapeutics SWOT Analysis
2.10.4 Nabriva Therapeutics Product and Services
2.10.5 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Community Acquired Pneumonia (CAP) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Community Acquired Pneumonia (CAP) Players Market Share
3.2.2 Top 10 Community Acquired Pneumonia (CAP) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Community Acquired Pneumonia (CAP) Revenue and Market Share by Regions
4.2 North America Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
4.3 Europe Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
4.5 South America Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
5 North America Community Acquired Pneumonia (CAP) Revenue by Countries
5.1 North America Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
5.2 USA Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
5.3 Canada Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
5.4 Mexico Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
6 Europe Community Acquired Pneumonia (CAP) Revenue by Countries
6.1 Europe Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
6.2 Germany Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
6.3 UK Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
6.4 France Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
6.5 Russia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
6.6 Italy Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue by Countries
7.1 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
7.2 China Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
7.3 Japan Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
7.4 Korea Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
7.5 India Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
8 South America Community Acquired Pneumonia (CAP) Revenue by Countries
8.1 South America Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
8.2 Brazil Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
8.3 Argentina Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Community Acquired Pneumonia (CAP) by Countries
9.1 Middle East & Africa Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
9.3 UAE Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
9.4 Egypt Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
9.5 South Africa Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Community Acquired Pneumonia (CAP) Revenue and Market Share by Type (2015-2020)
10.2 Global Community Acquired Pneumonia (CAP) Market Forecast by Type (2019-2024)
10.3 Chest X-ray/Radiography Revenue Growth Rate (2015-2025)
10.4 Sputum Gram Stain and/or Culture Revenue Growth Rate (2015-2025)
10.5 Blood Cultures Revenue Growth Rate (2015-2025)
11 Global Community Acquired Pneumonia (CAP) Market Segment by Application
11.1 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Application (2015-2020)
11.2 Community Acquired Pneumonia (CAP) Market Forecast by Application (2019-2024)
11.3 Hospitals and Clinics Revenue Growth (2015-2020)
11.4 Others Revenue Growth (2015-2020)
12 Global Community Acquired Pneumonia (CAP) Market Size Forecast (2021-2025)
12.1 Global Community Acquired Pneumonia (CAP) Market Size Forecast (2021-2025)
12.2 Global Community Acquired Pneumonia (CAP) Market Forecast by Regions (2021-2025)
12.3 North America Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
12.4 Europe Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
12.6 South America Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Community Acquired Pneumonia (CAP) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Community Acquired Pneumonia (CAP) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Community Acquired Pneumonia (CAP) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Community Acquired Pneumonia (CAP) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Community Acquired Pneumonia (CAP) Major Business
Table 7. Pfizer Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Community Acquired Pneumonia (CAP) Product and Solutions
Table 10. Pfizer Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Merck Corporate Information, Location and Competitors
Table 12. Merck Community Acquired Pneumonia (CAP) Major Business
Table 13. Merck Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2018-2019)
Table 14. Merck SWOT Analysis
Table 15. Merck Community Acquired Pneumonia (CAP) Product and Solutions
Table 16. Merck Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Biotest Corporate Information, Location and Competitors
Table 18. Biotest Community Acquired Pneumonia (CAP) Major Business
Table 19. Biotest Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 20. Biotest SWOT Analysis
Table 21. Biotest Community Acquired Pneumonia (CAP) Product and Solutions
Table 22. Biotest Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Astrazeneca Corporate Information, Location and Competitors
Table 24. Astrazeneca Community Acquired Pneumonia (CAP) Major Business
Table 25. Astrazeneca Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 26. Astrazeneca SWOT Analysis
Table 27. Astrazeneca Community Acquired Pneumonia (CAP) Product and Solutions
Table 28. Astrazeneca Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Melinta Therapeutics Corporate Information, Location and Competitors
Table 30. Melinta Therapeutics Community Acquired Pneumonia (CAP) Major Business
Table 31. Melinta Therapeutics Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 32. Melinta Therapeutics SWOT Analysis
Table 33. Melinta Therapeutics Community Acquired Pneumonia (CAP) Product and Solutions
Table 34. Melinta Therapeutics Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Bioaegis Therapeutics Corporate Information, Location and Competitors
Table 36. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Major Business
Table 37. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 38. Bioaegis Therapeutics SWOT Analysis
Table 39. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Product and Solutions
Table 40. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Paratek Pharmaceuticals Corporate Information, Location and Competitors
Table 42. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Major Business
Table 43. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 44. Paratek Pharmaceuticals SWOT Analysis
Table 45. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Product and Solutions
Table 46. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Kyorin Pharmaceutical Corporate Information, Location and Competitors
Table 48. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Major Business
Table 49. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 50. Kyorin Pharmaceutical SWOT Analysis
Table 51. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Product and Solutions
Table 52. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. C10 Pharma Corporate Information, Location and Competitors
Table 54. C10 Pharma Community Acquired Pneumonia (CAP) Major Business
Table 55. C10 Pharma Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 56. C10 Pharma SWOT Analysis
Table 57. C10 Pharma Community Acquired Pneumonia (CAP) Product and Solutions
Table 58. C10 Pharma Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Nabriva Therapeutics Corporate Information, Location and Competitors
Table 60. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Major Business
Table 61. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Total Revenue (USD Million) (2017-2018)
Table 62. Nabriva Therapeutics SWOT Analysis
Table 63. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Product and Solutions
Table 64. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) by Players (2015-2020)
Table 66. Global Community Acquired Pneumonia (CAP) Revenue Share by Players (2015-2020)
Table 67. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Regions (2015-2020)
Table 69. North America Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
Table 70. North America Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Table 71. Europe Community Acquired Pneumonia (CAP) Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Community Acquired Pneumonia (CAP) Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Community Acquired Pneumonia (CAP) Revenue by Countries (2015-2020)
Table 74. South America Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Table 77. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) by Type (2015-2020)
Table 78. Global Community Acquired Pneumonia (CAP) Revenue Share by Type (2015-2020)
Table 79. Global Community Acquired Pneumonia (CAP) Revenue Forecast by Type (2021-2025)
Table 80. Global Community Acquired Pneumonia (CAP) Revenue by Application (2015-2020)
Table 81. Global Community Acquired Pneumonia (CAP) Revenue Share by Application (2015-2020)
Table 82. Global Community Acquired Pneumonia (CAP) Revenue Forecast by Application (2021-2025)
Table 83. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Community Acquired Pneumonia (CAP) Picture
Figure 2. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type in 2019
Figure 3. Chest X-ray/Radiography Picture
Figure 4. Sputum Gram Stain and/or Culture Picture
Figure 5. Blood Cultures Picture
Figure 6. Community Acquired Pneumonia (CAP) Revenue Market Share by Application in 2019
Figure 7. Hospitals and Clinics Picture
Figure 8. Others Picture
Figure 9. Global Community Acquired Pneumonia (CAP) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Community Acquired Pneumonia (CAP) Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Community Acquired Pneumonia (CAP) Revenue Market Share in 2019
Figure 18. Global Top 10 Players Community Acquired Pneumonia (CAP) Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Regions (2015-2020)
Figure 22. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Regions in 2018
Figure 23. North America Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 24. Europe Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 26. South America Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 28. North America Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Figure 29. North America Community Acquired Pneumonia (CAP) Revenue Market Share by Countries in 2019
Figure 30. USA Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 31. Canada Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 33. Europe Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Community Acquired Pneumonia (CAP) Revenue Market Share by Countries in 2019
Figure 35. Germany Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 36. UK Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 37. France Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 38. Russia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 39. Italy Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Community Acquired Pneumonia (CAP) Revenue Market Share by Countries in 2019
Figure 42. China Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 43. Japan Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 44. Korea Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 45. India Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 47. South America Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Figure 48. South America Community Acquired Pneumonia (CAP) Revenue Market Share by Countries in 2019
Figure 49. Brazil Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 54. UAE Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2015-2020)
Figure 57. Global Community Acquired Pneumonia (CAP) Revenue Share by Type (2015-2020)
Figure 58. Global Community Acquired Pneumonia (CAP) Revenue Share by Type in 2019
Figure 59. Global Community Acquired Pneumonia (CAP) Market Share Forecast by Type (2021-2025)
Figure 60. Global Chest X-ray/Radiography Revenue Growth Rate (2015-2020)
Figure 61. Global Sputum Gram Stain and/or Culture Revenue Growth Rate (2015-2020)
Figure 62. Global Blood Cultures Revenue Growth Rate (2015-2020)
Figure 63. Global Community Acquired Pneumonia (CAP) Revenue Share by Application (2015-2020)
Figure 64. Global Community Acquired Pneumonia (CAP) Revenue Share by Application in 2019
Figure 65. Global Community Acquired Pneumonia (CAP) Market Share Forecast by Application (2021-2025)
Figure 66. Global Hospitals and Clinics Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Community Acquired Pneumonia (CAP) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Community Acquired Pneumonia (CAP) Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
Figure 72. Europe Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
Figure 74. South America Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Community Acquired Pneumonia (CAP) Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel

---